ArticleAmerican journal of translational research2025
Efficacy and influencing factors of thrombolytic therapy in patients with pulmonary embolism complicated y pulmonary arterial hypertension.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy of thrombolysis in patients with pulmonary embolism (PE) and pulmonary hypertension (PH), and identify factors influencing therapeutic outcomes.
methodsA retrospective analysis was conducted on 148 patients diagnosed with PE complicated by PH who received thrombolytic treatment at Tianjin Medical University General Hospital and Inner Mongolia People's Hospital between January 2022 and August 2024. Changes in inflammatory markers, blood gas parameters, and coagulation function indicators before and after treatment were compared, and the overall treatment efficacy rate was calculated. Patients were stratified based on therapeutic response, and a binary logistic regression model was employed to analyze factors associated with treatment effectiveness. The predictive value of these factors was assessed using receiver operating characteristic (ROC) curve analysis.
resultsWithin 24 hours post-thrombolysis, primary symptoms and clinical signs significantly improved. Specifically, respiratory rate (RR), heart rate (HR), and partial pressure of carbon dioxide (PaCO
conclusionThrombolytic therapy effectively improves clinical symptoms, physical signs, hemodynamic parameters, and cardiac function in patients with PE complicated by PH. Furthermore, in clinical practice, early monitoring of inflammatory markers such as PaCO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.